NuProbe

  • Total Funding$53 M

OverviewSuggest Edit

NuProbe is a company developing technologies in genomics for disease detection. It develops a PCR-based (polymerase chain reaction) enrichment method called blocker displacement amplification for selective amplification of low abundant sequence variants in a background of wildtype DNA.

TypePrivate
Founded2016
HQCambridge, MA, USMap
Websitenuprobe.com
Employee Ratings3.8

Recent NewsAll News

Latest Updates

Employees (est.) (Aug 2022)73(+2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at NuProbe

Yingshuang Chai

Yingshuang Chai

Co-Founder & CEO and Chairman of the Board of Directors
Nicolas Garreau de Loubresse

Nicolas Garreau de Loubresse

Director of Business Development
Yundi Chen

Yundi Chen

Co-Founder & Ex VP, Scientific Research Service
Janet Huang

Janet Huang

Associate Director of Operations
Hu Ouyang

Hu Ouyang

VP of Manufacturing
Song Gao

Song Gao

VP of Marketing & TSS
Show more

NuProbe Office Locations

NuProbe has offices in Cambridge and Houston
Cambridge, MA, US (HQ)
85 Bolton St
Houston, TX, US
2575 W Bellfort Ave #210
Houston, TX, US
9350 Kirby Dr #200
Show all (4)

NuProbe Financials and Metrics

Summary Metrics

Founding Date

2016

NuProbe total Funding

$53 m

NuProbe latest funding size

$42 m

Time since last funding

2 years ago

NuProbe investors

WuXi AppTec, Yonghua Capital, Sequoia Capital China, BioTrack Capital, Serica Partners, Taifu Capital, Panlin Capital, Juming Capital, Tuobang Capital, Ruomu Capital
NuProbe's latest funding round in January 2021 was reported to be $42 m. In total, NuProbe has raised $53 m
Show all financial metrics

NuProbe Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

Learn more about our premium products
SecurityScorecard logo

NuProbe Online and Social Media Presence

NuProbe's Trends

Embed Graph

NuProbe News and Updates

June 02, 2022

NuProbe Closes $50M in New Fundraising

Houston, TX, June 02, 2022 (GLOBE NEWSWIRE) -- NuProbe Global, a genomics and molecular diagnostics company, announces the close of its $50M fundraising, co-led by AstraZeneca-CICC Fund, CR-CP Life Science Fund, and Panlin Capital.  Existing NuProbe investors Sequoia Capital China, Biotrack Capita…
May 20, 2022

Global DNA Nanotechnology Market Report 2022-2027 Featuring Major Players - NuProbe USA, tilibit nanosystems, GATTAquant, Genisphere, Inovio Pharmaceuticals, & Novartis

DUBLIN, May 20, 2022 /PRNewswire/ -- The "Global DNA Nanotechnology Market, By Type, By Application, By End User, By Region, Competition Forecast and Opportunities, 2017-2027" report has been added to ResearchAndMarkets.com's offering. Global DNA nanotechnology market is projected to...
April 19, 2022

NuProbe Published Method for Designing Highly Multiplex PCR Primer Sets

Houston, April 19, 2022 (GLOBE NEWSWIRE) -- NuProbe, a global genomics and molecular diagnostics company, announces its recent publication in Nature Communications describing a massively multiplexed PCR primer design algorithm, named Simulated Annealing Design using Dimer Likelihood Estimation (SA…
April 05, 2022

NuProbe QASeq Technology Enables Simultaneous Ultrasensitive Detection of CNVs and Mutations from FFPE Tissue and cfDNA

Houston, April 05, 2022 (GLOBE NEWSWIRE) -- NuProbe, a global genomics and molecular diagnostics company, announced new published data in Nature Communications describing the use of Quantitative Amplicon Sequencing (QASeq) to simultaneously detect copy number variations (CNVs) and mutations from t…
September 07, 2021

NuProbe Global Adopts Bionano’s Saphyr® System to Develop Products in Reproductive Health and Oncology Applications

SAN DIEGO and SHANGHAI, China, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that NuProbe Global, a global molecular diagnostics company based in Shanghai, China and Houston, Texas, has adopted Bionano’s Saphyr system for optical genome mapping (OGM) to i…
September 06, 2021

NuProbe technology Enables Rapid Ultrasensitive Mutation Detection on Nanopore Platforms

HOUSTON, Sept. 6, 2021 /PRNewswire/ -- NuProbe scientists and collaborators recently published a new method for sensitive detection of somatic mutations using Oxford Nanopore sequencing platforms. The method, termed oncogene concatenated enriched amplicon nanopore sequencing (OCEANS),...
Show more

 NuProbe Frequently Asked Questions

  • When was NuProbe founded?

    NuProbe was founded in 2016.

  • Who are NuProbe key executives?

    NuProbe's key executives are Yingshuang Chai, Nicolas Garreau de Loubresse and Yundi Chen.

  • How many employees does NuProbe have?

    NuProbe has 73 employees.

  • Who are NuProbe competitors?

    Competitors of NuProbe include Serimmune, Sirigen and Rapture Biotech.

  • Where is NuProbe headquarters?

    NuProbe headquarters is located at 85 Bolton St, Cambridge.

  • Where are NuProbe offices?

    NuProbe has offices in Cambridge and Houston.

  • How many offices does NuProbe have?

    NuProbe has 4 offices.